Ever Supreme Bio Technology Co., Ltd (6712)
Market Closed
11 Aug, 05:30
TWSE TWSE Primary NT$
151. 00
-5.5
-3.5144%
NT$
14.04B Market Cap
- P/E Ratio
24% Div Yield
416,771 Volume
- Eps
NT$ 156.5
Previous Close Want to track 6712 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
6712 closed today lower at NT$151, a decrease of -3.5144% from yesterday's close, completing a monthly decrease of -5.0314% or -NT$8. Over the past 12 months, 6712 stock lost -9.0361%.
6712 pays dividends to its shareholders, with the most recent payment made on May 08, 2026. The next estimated payment will be in In 8 months on May 08, 2027 for a total of NT$3.5.
The last earnings report, released on May 08, 2026, missed the consensus estimates by -0.99%. On average, the company has fell short of earnings expectations by -1.515%, based on the last three reports.
Ever Supreme Bio Technology Co., Ltd has completed 5 stock splits, with the recent split occurring on May 14, 2026.
The company's stock is traded on one exchange.
Ever Supreme Bio Technology Co., Ltd (6712) FAQ
What is the stock price today?
The current price is NT$151.00.
On which exchange is it traded?
Ever Supreme Bio Technology Co., Ltd is listed on TWSE.
What is its stock symbol?
The ticker symbol is 6712.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 24%.
What is its market cap?
As of today, the market cap is 14.04B.
Has Ever Supreme Bio Technology Co., Ltd ever had a stock split?
Ever Supreme Bio Technology Co., Ltd had 5 splits and the recent split was on May 14, 2026.
Ever Supreme Bio Technology Co., Ltd Profile
| Biotechnology Industry | Healthcare Sector | - CEO | TWSE Exchange | TW0006712003 ISIN |
| Taiwan Country | - Employees | 16 Apr 2026 Last Dividend | 14 May 2026 Last Split | - IPO Date |
Overview
Ever Supreme Bio Technology Co., Ltd is a pioneering entity in the bio-technological sector, focusing on the development of innovative therapies derived from human mesenchymal stem cells and immune cells. Since its establishment in 2016 and based in Taichung, Taiwan, the company has been at the forefront of researching, developing, and manufacturing advanced drug products. Its endeavor to address critical medical conditions such as myocardial infarction, stroke, malignant brain tumors, degenerative osteoarthritis, and spinal cord injuries through cutting-edge biotechnological solutions reflects a commitment to improving patient outcomes and advancing healthcare.
Products and Services
Ever Supreme Bio Technology Co., Ltd offers a diversified portfolio of drug candidates and biotechnological products, underpinned by its leading-edge research in mesenchymal stem cells and immune cells:
- UMC01: This pioneering drug candidate is currently in Phase I clinical trials. It has been developed with the potential to treat myocardial infarction and stroke, two of the most prevalent and devastating cardiovascular conditions. Through its novel approach, UMC01 aims to revolutionize the therapeutic landscape for patients suffering from these acute ailments.
- ADCV01: Another significant breakthrough from Ever Supreme Bio Technology is ADCV01, which is in Phase II clinical trials. Specifically targeting malignant brain tumors, this drug candidate embodies the company's commitment to combatting cancer. ADCV01's innovative formulation is at the forefront of advancing cancer therapy, offering hope to patients battling this challenging disease.
- CAR001: This product represents Ever Supreme Bio Technology's foray into the realm of immunotherapy. CAR001 is a chimeric antigen receptor immune cell product, embodying the latest advancements in cancer treatment. By harnessing the body's own immune system, CAR001 aims to provide a powerful tool against various types of cancer, highlighting the company's commitment to leading-edge therapeutic developments.
- Bone-Marrow Stem Cells (BMSC): Focused on treating a range of conditions including chronic stroke, degenerative osteoarthritis, and spinal cord injuries, BMSC underscores the company's versatility and innovation in stem cell therapy. Through its specialized bone-marrow stem cells, Ever Supreme Bio Technology provides a beacon of hope for patients suffering from these debilitating conditions, paving the way for new therapeutic possibilities.
Contact Information
Address: No. 30, Keya Road
Phone: 886 4 2325 2888
Website: https://www.ever-supreme.com.tw
